We evaluated the clinical efficacy of α1-blocker naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia (BPH).Methods:
A total of 29 patients (range 50–83 years of age, mean 66.7 years) who had severe storage symptoms associated with BPH were studied. The inclusion criteria were (i) a total of seven or more points in storage symptom scores (frequency, urgency and nocturia) of the International Prostate Symptom Score (I-PSS) and (ii) a quality of life (QOL) index of two or more. Subjective (I-PSS and QOL index) and objective (uroflowmetry, post-void residual and filling cystometry) parameters were evaluated before and 3 months after treatment with naftopidil.Results:
Total I-PSS significantly decreased after treatment, with significant improvement of both storage and voiding symptoms scores and QOL index. Improvement of QOL index was most correlated with the reduction of storage symptoms scores. In nine patients who had involuntary detrusor contractions during filling cystometry before treatment, bladder volume at first desire to void significantly increased (from a mean of 174 to 260 mL), and involuntary detrusor contractions disappeared in three patients after treatment.Conclusion:
Naftopidil improves not only voiding symptoms, but also storage symptoms associated with BPH, and is effective for improving bladder storage function in patients with detrusor overactivity.